Platypus Technologies, LLC | Date: 2014-03-12
Provided herein is technology relating to detecting gaseous analytes and particularly, but not exclusively, to devices and methods related to detecting gaseous analytes by monitoring changes in liquid crystals upon exposure to the gaseous analytes.
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 145.76K | Year: 2016
DESCRIPTION provided by applicant The air we breathe can contain dozens of toxins The National Institute of Environmental Health Sciences NIEHS strategic plan for includes a major focus on andquot enhancing our ability to quantify individual exposures and responses to environmental toxins andquot Similarly the US Environmental Protection Agency EPA is increasing its emphasis on community monitoring so that citizens may better understand their exposures to toxins However equipping large numbers of individuals and or geographic sites with available monitoring equipment capable of accurately measuring low levels of toxins would be prohibitively expensive Therefore affordable devices capable of measuring personal exposures to toxic gases are urgently needed Moreover available andquot simpleandquot toxic gas monitors have presented difficulties of operation and interpretation when deployed by lay personnel for community monitoring initiatives Therefore personal exposure monitors must also be easy to use and interpret if personal monitoring is to be widely adopted One air pollutant that is challenging to measure affordably at low levels with specificity and accuracy is formaldehyde HCHO This carcinogen is emitted from building materials among other sources and can pollute homes and workplaces where the materials are installed or manufactured Providing simple affordable means of monitoring HCHO exposure would provide citizens with better actionable information epidemiologists with better data with which to assess health risks and regulators with information needed to develop effective defensible policies Platypus Technologies has developed an approach to monitoring HCHO exposure that combines the companyandapos s proprietary liquid crystal LC sensing platform with a novel sensing mechanism The platform is amenable to zero power readouts and the sensors are inherently small and light weight facilitating comfortable deployment on people Platypus has commercialized the ClearSense tm hydrogen sulfide dosimeter based on LC technology for the industrial hygiene market and now proposes to leverage this expertise for the more challenging task of HCHO detection The LC sensing platform is uniquely amenable to a novel surface chemistry strategy for detecting HCHO that is designed to improve specificity over currently available sensors The strategy involves fabricating a chemically reactive surface on which LCs align parallel to it On exposure to HCHO the LCs realign perpendicular to the surface This realignment causes sensors to change from bright to dark when viewed through crossed polarizers The long term goal is a chemical dosimeter product for HCHO suitable for personal exposure monitoring To minimize fabrication costs and improve performance for long term monitoring we propose to modify sensor design from the Clear Sense product concept by i supplanting the use of gold on glass sensor surfaces with saline on glass to save costs and extend sensor stability ii reducing sensor surface area further reducing costs and iii replacing the LCs traditionally used for sensors with LCs that have greater resilience to changes in temperature and moisture an option not previously possible that is afforded by the novel detection chemistry PUBLIC HEALTH RELEVANCE The National Institute of Environmental Health Sciences NIEHS strategic plan for includes a major focus on andquot enhancing our ability to quantify individual exposures and responses to environmental toxins andquot Equipping large numbers of individuals with reliable toxics monitoring equipment would provide valuable exposure data for individuals for epidemiologists and for regulators but is currently prohibitively expensive and for many overly complicated We propose to determine the feasibility of a novel strategy for fabricating low cost light weight dosimeters for personal monitoring of exposure to the carcinogen formaldehyde so that broad communities regulators and epidemiologists may better understand community and individual health risks
Agency: NSF | Branch: Standard Grant | Program: | Phase: | Award Amount: 149.99K | Year: 2012
This Small Business Innovation Research (SBIR) Phase I project will lead to the development of a new class of liquid crystal (LC)-based direct-read monitors (DRMs) for detection of nitrogen dioxide (NO2) present in air at construction sites. The approach to development of DRMs that is described in this proposal is based on the innovative use of LC materials to detect and report molecular interactions on chemically functionalized surfaces. Results obtained under Phase I research will demonstrate that sensors comprised of a chemically functionalized surface supporting a thin film of nematic LC can detect NO2 in air at levels required to meet worker safety standards established by regulatory agencies.
The broader impact of this research is the reduction of hazardous chemicals exposure risk to 139 million US citizens at their work place. This Phase I SBIR proposal is focused on protecting the health of 9 million workers in the US construction industry, workers who have been documented to be at increased risk of chronic exposure to NO2 in air due to regular use of various tools, equipments, and vehicles powered by diesel engines. This DRM platform, while initially focused on detection of NO2 within construction zones, has the potential to be broadly useful for detection of a range of hazardous gases encountered in occupational settings in the US.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 144.34K | Year: 2014
Project Summary The goal of this SBIR project is to design and develop an efficient, automation- compatible Directed Cell Migration (DCM) 96-well Assay that distinguishes chemokinetic from chemotactic behavior. Cell migration is currently assayed using trans-membrane well inserts, microfluidic systems and various versions of scratch assays. These methods are expensive and provide inconsistent data. Due to its importance in cancer and associated metastatic processes, cell migration is intensively studied and in vitro cell migration assays are routinely used in drug discovery programs aimed at identifying new cancer therapeutics. An important characteristic of cancer cells is their ability to detect chemoattractant gradients and migrate in response to them. Amajor barrier to efficient screening of candidate cancer therapeutics affecting directed cell migration is the lack of affordable cell based assays that are robust, physiologically relevant, reproducible and cost-effective to perform. Platypus Technologi
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 147.45K | Year: 2014
DESCRIPTION (provided by applicant): The goal of this SBIR project is to design and develop an efficient, physiologically relevant and cost-effective 96-well 3-D Cell Migration Assay that is compatible with mid-high throughput/high content assay platforms.Due to its importance in cancer and associated metastatic processes, cell migration is intensively studied and in vitro cell migration assays are routinely used in drug discovery programs aimed at identifying new cancer therapeutics. Cell migration studies of cells grown in 3-D biomimetic matrices are currently performed primarily using trans-membrane well inserts and microfluidic systems. These methods are expensive, laborious and provide inconsistent data. Moreover, these assays compromise on an important characteristic of the in vivo environment: the unique spatial arrangement of cells that facilitates their ability to exhibit normal physiological phenotypes and functions. A major barrier to efficient screening of candidate cancer therapeutics affe